… Eight kinds of KRAS mutations were observed in this study with G12C reported in over a …
Preclinical studies further demonstrate that combining MEK inhibitors with PI3K inhibitors or …

… Our results suggest that although MEK inhibitors show promise in colorectal cancer, KRAS/…
surrogate marker for mutant BRAF or KRAS mutation–positive colorectal cancer tumor cells. …

… have all been implicated with resistance against MEK inhibitor therapy in KRAS mutated …
to MEK inhibitors in CRCs harboring BRAF mutations. Thus, dual targeted inhibition of MEK and …

… cell lines, by measuring the reduction of phospho-MEK adaptive induction after … MEK
inhibitors led to enhanced antiproliferative activity and MAPK pathway suppression in KRAS-mutant …

… , there were trends toward greater improvement in OS, PFS, and ORR compared with other
KRAS mutations [45]. A phase 1/1b study evaluated the efficacy and safety of trametinib plus …

… Most KRAS mutations were located at codon 12 and all … reflects organ-specific roles of the
KRAS and BRAF oncogenes. … with KRAS or BRAF mutations be considered for MEK inhibitor (…

… (F) The combination of EGFR and BRAF inhibitors or EGFR and MEK inhibitors can … Kras
mutations (5), we systematically analyzed the frequency of known hotspot mutations in KRAS, …

… mechanism of resistance to MEK inhibitors in KRASMT CRC mediated by c-MET via JAK1/2-STAT3
that is acutely induced as a consequence of suppression of MEK-dependent, …

… To confirm the essential role of the STAT3 pathway in resistance to MEK inhibition, we
knocked down STAT3 in K-Ras mutant AsPC-1 cell line. In cell viability assays, knockdown of …

… rationally combine these two modalities to treat KRAS mutant lung cancers. In addition to
the essential role of MEKis in RAS-MEK-ERK signaling suppression during the tumorigenesis …